Insulet (MIL:1PODD) Inventories, Raw Materials & Components: €184 Mil (As of Mar. 2026)


MIL:1PODD Insulet Corp MIL:1PODD
62 GF Score
Price €140.20
GF Value €345.27
Valuation Significantly Undervalued
View Full Analysis

What is Insulet Inventories, Raw Materials & Components?

Insulet MIL:1PODD 62 Inventories, Raw Materials & Components is €184 Mil as of Mar. 2026. GuruFocus rates MIL:1PODD with a GF Score™ of 62/100 and a GF Value™ of €345.27 (Significantly Undervalued).

Insulet's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €184 Mil.

Insulet's quarterly raw materials increased from Sep. 2025 (€155 Mil) to Dec. 2025 (€166 Mil) and increased from Dec. 2025 (€166 Mil) to Mar. 2026 (€184 Mil).

Insulet's annual raw materials increased from Dec. 2023 (€108 Mil) to Dec. 2024 (€150 Mil) and increased from Dec. 2024 (€150 Mil) to Dec. 2025 (€166 Mil).

Insulet Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Insulet's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet Inventories, Raw Materials & Components Chart

Insulet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.95 74.67 108.39 149.65 165.76

Insulet Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 151.42 155.89 154.55 165.76 183.90
MIL:1PODD
62GF Score
Insulet Corp MIL:1PODD
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insulet Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €184 Mil mean?
Insulet (MIL:1PODD) has a Inventories, Raw Materials & Components of €184 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Insulet and its competitors.
Is Insulet's Inventories, Raw Materials & Components too high?
Insulet's current Inventories, Raw Materials & Components is €184 Mil. Overall, Insulet has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Inventories, Raw Materials & Components compare to GMED and PEN?
Insulet's Inventories, Raw Materials & Components of €184 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Medical Devices & Instruments company?
A good Inventories, Raw Materials & Components depends on the Medical Devices & Instruments industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Insulet and its competitors. Insulet's current Inventories, Raw Materials & Components is €184 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (MIL:1PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is €345.27, compared to a current price of €140.20 — trading 59.4% below its estimated fair value. The current Inventories, Raw Materials & Components is €184 Mil. Insulet's overall GF Score™ is 62/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Insulet (MIL:1PODD), the current Inventories, Raw Materials & Components is €184 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (MIL:1PODD) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of €140.20 is trading 59.4% below its estimated GF Value™ of €345.27. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for MIL:1PODD:

  • Inventories, Raw Materials & Components: €184 Mil
  • GF Value™: €345.27 vs. price of €140.20 (59.4% below fair value)
  • GF Score™: 62/100

No single metric tells the full story. See the MIL:1PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
62GF Score

Get the complete analysis for MIL:1PODD

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€140.20
Price
€345.27
GF Value